• by bcarlson@marketresearch.com
  • December 2 2014

Demand Surges for Biologics Production As Capacity Nears Limit

Demand Surges for Biologics Production As Capacity Nears Limit

The biopharmaceutical and vaccine production market is estimated to reach $41 billion in 2014, according to our  recent report on the industry.   Firms are near capacity with the amount of biologic development.     It is estimated there are more than 400 biotech drug products and vaccines targeting hundreds of the diseases in the pipeline. Over the next several years, as the number of biologics produced increases, the demand for biologic manufacturing capacity will continue to increase.

Demand continues to increase for biopharmaceutical production using mammalian cell culture and microbial fermentation processes. Capacity utilization for integrated biopharmaceutical manufacturers and large contract manufacturing organizations (CMO) are presently estimated at 81% for microbial fermentation and 71% for mammalian cell culture.   This is a change according to the report, the economic downturn and lower approvals rates for new molecular entities dampened the demand for biopharmaceutical contract manufacturing services earlier this decade.

Kalorama expects demand to grow and for the market to see double digit growth over the next five years.

The report, Biopharmaceutical and Vaccine Production Markets (Mammalian Cell Production, Microbial Cell Production Market, Monoclonal Antibody Manufacturing, Other Recombinant Protein Manufacturing, Vaccine Manufacturing, Insulin Manufacturing Market) is available from Kalorama Information.  http://www.kaloramainformation.com/Biopharmaceutical-Vaccine-Production-8357580/